APVO
Aptevo Therapeutics Inc.
There isn't enough reported data to score APVO yet.
APVO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
APVO's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
APVO PE Valuation
APVO has no meaningful PE right now: it lost money over the past year.
APVO Forward outlook
There aren't enough analyst estimates for APVO to show an outlook.
APVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$1,347,984.00 | -280% |
| Q2 2023 | -$1,934,064.00 | -344% |
| Q1 2023 | $2,057,140.80 | +$5,561,899.20 |
| Q4 2022 | $920,145.60 | +$4,477,651.20 |
| Q3 2022 | $750,182.40 | +$4,700,361.60 |
| Q2 2022 | $791,208.00 | +$5,134,060.80 |
| Q1 2022 | -$3,504,758.40 | +$1,043,222.40 |
| Q4 2021 | -$3,557,505.60 | -$492,307.20 |
APVO has swung to a loss: it lost $1,347,984.00 per share over the past year, after a profit the year before.
APVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $3.1M | +29% |
| Q4 2021 | $3.7M | +54% |
| Q3 2021 | $3.1M | +112% |
| Q2 2021 | $3.1M | +558% |
| Q4 2020 | $2.4M | -74% |
| Q3 2020 | $1.5M | -84% |
APVO's revenue has slid since its 2019 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | -180% | +104 points |
| Q4 2021 | -110% | +177 points |
| Q3 2021 | -153% | +274 points |
| Q2 2021 | -184% | N/A |
| Q1 2021 | -285% | N/A |
| Q4 2020 | -287% | -202 points |
| Q3 2020 | -427% | -310 points |
| Q4 2019 | -85% | N/A |
APVO's operating margin was −180% last quarter, up 104 points from the same quarter a year ago.
APVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.5M | +$1.6M |
| Q1 2026 | -$8M | -$1.4M |
| Q4 2025 | -$5.2M | +$523K |
| Q3 2025 | -$6.7M | -$1.5M |
| Q2 2025 | -$7.1M | -$940K |
| Q1 2025 | -$6.6M | +$76K |
| Q1 2024 | -$6.7M | -246% |
| Q4 2022 | -$5.9M | -$1.9M |
APVO has burned cash in almost every quarter: −$25M over the past year, against −$25M the year before.
APVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +136K shares |
| 1 year | +29433% | +1.2M shares |
| 3 years | +13292833% | +1.2M shares |
| 5 years | +19939300% | +1.2M shares |
APVO has 1M diluted shares, up 29433% from a year ago.
APVO Net Leverage
APVO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
APVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 2.8 | Oversold |
APVO's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
APVO PE vs Healthcare Sector
| Metric | APVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
APVO has no meaningful PE right now: it lost money over the past year.
APVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.49 | 56% below |
| 20 week MA | $2.56 | 74% below |
| 50 week MA | $5.60 | 88% below |
| 100 week MA | $233.4 | 100% below |
| 200 week MA | $171,716.8 | 100% below |
APVO is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
APVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4,849,225.9 | $20,747,232.0 | +328% |
| 2021 | $20,747,232.0 | $4,612,449.6 | -78% |
| 2022 | $4,612,449.6 | $1,213,185.6 | -74% |
| 2023 | $1,213,185.6 | $106,080.5 | -91% |
| 2024 | $106,080.5 | $1,731.6 | -98% |
| 2025 | $1,731.6 | $10.9 | -99% |
| 2026 YTD | $10.9 | $0.66 | -94% |
APVO has finished five years in a row lower, and it's down 94% so far in 2026.